Xintela Past Earnings Performance
Past criteria checks 0/6
Xintela's earnings have been declining at an average annual rate of -4.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 72.1% per year.
Key information
-4.1%
Earnings growth rate
38.0%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | 72.1% |
| Return on equity | n/a |
| Net Margin | -1,264.0% |
| Next Earnings Update | 28 Feb 2025 |
Recent past performance updates
Revenue & Expenses Breakdown
How Xintela makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3 | -40 | 11 | 34 |
| 30 Jun 24 | 0 | -41 | 11 | 36 |
| 31 Mar 24 | 0 | -49 | 12 | 42 |
| 31 Dec 23 | 0 | -54 | 13 | 46 |
| 30 Sep 23 | 0 | -59 | 14 | 55 |
| 30 Jun 23 | 0 | -65 | 14 | 57 |
| 31 Mar 23 | 0 | -66 | 15 | 57 |
| 31 Dec 22 | 0 | -66 | 17 | 56 |
| 30 Sep 22 | 0 | -67 | 16 | 51 |
| 30 Jun 22 | 0 | -68 | 16 | 53 |
| 31 Mar 22 | 0 | -64 | 14 | 51 |
| 31 Dec 21 | 0 | -60 | 12 | 50 |
| 30 Sep 21 | 0 | -68 | 12 | 49 |
| 30 Jun 21 | 0 | -60 | 12 | 44 |
| 31 Mar 21 | 0 | -54 | 12 | 41 |
| 31 Dec 20 | 0 | -50 | 11 | 38 |
| 30 Sep 20 | 0 | -40 | 10 | 39 |
| 30 Jun 20 | 0 | -40 | 9 | 36 |
| 31 Mar 20 | 0 | -42 | 8 | 36 |
| 31 Dec 19 | 0 | -44 | 9 | 35 |
| 30 Sep 19 | 1 | -37 | 9 | 28 |
| 30 Jun 19 | 1 | -33 | 8 | 25 |
| 31 Mar 19 | 1 | -28 | 8 | 19 |
| 31 Dec 18 | 2 | -26 | 8 | 18 |
| 30 Sep 18 | 1 | -24 | 7 | 16 |
| 30 Jun 18 | 0 | -25 | 7 | 17 |
| 31 Mar 18 | 0 | -24 | 6 | 18 |
| 31 Dec 17 | 0 | -22 | 6 | 16 |
| 30 Sep 17 | 0 | -20 | 5 | 15 |
| 30 Jun 17 | 0 | -18 | 5 | 15 |
| 31 Mar 17 | 0 | -18 | 5 | 15 |
| 31 Dec 16 | 0 | -18 | 4 | 15 |
| 30 Sep 16 | 0 | -18 | 6 | 14 |
| 30 Jun 16 | 1 | -17 | 5 | 12 |
| 31 Mar 16 | 1 | -14 | 4 | 10 |
| 31 Dec 15 | 1 | -12 | 3 | 9 |
| 31 Dec 14 | 0 | -8 | 2 | 6 |
Quality Earnings: XINT is currently unprofitable.
Growing Profit Margin: XINT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: XINT is unprofitable, and losses have increased over the past 5 years at a rate of 4.1% per year.
Accelerating Growth: Unable to compare XINT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XINT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: XINT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.